- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00201786
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
April 25, 2016 updated by: Craig Hofmeister, Ohio State University Comprehensive Cancer Center
This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.
Study Overview
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have biopsy proven grade II-IV acute GVHD refractory to systemic corticosteroids
- No chronic GVHD
- Age ≥ 18 years
- Evidence of myeloid engraftment (ANC ≥ 0.5 x 109/l)
- Performance status 0-3
Exclusion Criteria:
- Patients on mechanical ventilation or who have resting O2 saturation <90% by pulse-oximetry.
- Patients on renal dialysis or who have an estimated creatinine clearance of < 30 ml/min/1.73 m2.
- Patients with documented clinical infection (progressive symptoms despite antibiotics or continued fever) cannot be enrolled on study until infection is controlled.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pentostatin
Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days.
Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
|
Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days.
Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the response rate (complete and partial) to treatment with pentostatin in steroid-refractory acute GVHD (graft-versus-host disease).
Time Frame: up to 2 years
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Investigate the pharmacokinetics of pentostatin in patients with acute GVHD to correlate the response with area under the curve (AUC).
Time Frame: up to 2 years
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Craig Hofmeister, MD, Ohio State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
July 1, 2013
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 20, 2005
Study Record Updates
Last Update Posted (Estimate)
April 27, 2016
Last Update Submitted That Met QC Criteria
April 25, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-0301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft-Versus-Host Disease
-
University of LiegeTerminatedChronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host DiseaseBelgium
-
Jazz PharmaceuticalsCompletedAcute-graft-versus-host Disease | Graft-versus-host DiseaseUnited States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
-
Mesoblast, Inc.Quintiles, Inc.CompletedGrade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host DiseaseUnited States
-
Grupo Espanol de trasplantes hematopoyeticos y...CompletedChronic Graft-Versus-Host DiseaseSpain
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedGraft-Versus-Host DiseaseUnited States
-
M.D. Anderson Cancer CenterCompleted
-
John LevineCompletedGVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-diseaseUnited States
-
AltruBio Inc.CompletedSteroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host DiseaseUnited States
-
Jonsson Comprehensive Cancer CenterWithdrawnAcute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host DiseaseUnited States
Clinical Trials on Pentostatin
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedGraft Versus Host DiseaseUnited States
-
Astex Pharmaceuticals, Inc.TerminatedAcute Graft Versus Host DiseaseUnited States
-
OncoVista, Inc.AAIPharmaUnknownRefractory TdT-Positive LeukemiaUnited States
-
University of RochesterWithdrawnActive Chronic Graft Versus Host DiseaseUnited States
-
Pharmatech OncologyCompletedLymphoma | LeukemiaUnited States
-
Boston Medical CenterNational Cancer Institute (NCI)Completed
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Astex Pharmaceuticals, Inc.CompletedLymphoma | LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | LeukemiaUnited States
-
Heidelberg UniversityLudwig-Maximilians - University of Munich; Universitätsmedizin Mannheim; Diakonie... and other collaboratorsUnknownB-Cell Chronic Lymphocytic Leukemia | B-Cell Non-Hodgkin's Lymphoma | Immunocytoma/Morbus Waldenström